Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will likely be releasing its earnings data after the market closes on Thursday, March 6th. Analysts expect Arcturus Therapeutics to post earnings of ($0.33) per share and revenue of $44.64 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Arcturus Therapeutics Stock Down 1.2 %

Shares of ARCT stock opened at $15.49 on Wednesday. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The stock has a market cap of $419.58 million, a P/E ratio of -6.98 and a beta of 2.62. The business has a fifty day simple moving average of $17.03 and a 200-day simple moving average of $18.68.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ARCT. HC Wainwright restated a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Finally, BTIG Research started coverage on Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $65.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.